ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2020
Interleukin 23 and autoimmune diseases: current and possible future therapies.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06563323 (A Single-arm Open-label Study Assessing Short-term), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-arm Open-label Study Assessing Short-term (Week 6, 16) and Long-term (Week 32) Efficacy of Guselkumab in Adult Participants With Pyoderma Gangrenosum
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-Analysis of the Efficacy and Safety of Interleukin-23-Targeted Drugs in the Treatment of Moderate-to-Severe Psoriasis.Contrast media & molecular imaging · 2022Pooled it
- Pharmacogenomic insights: IL-23R and ATG-10 polymorphisms in Sorafenib response for hepatocellular carcinoma.Clinical and experimental medicine · 2025Trial
- Immune system modifications in atypical parkinsonism related to autoimmunity - a case control study.Neurodegenerative disease management · 2026Article
- Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.Leukemia · 2026Article
- Genetic inhibition of IL-12β suppresses systolic overload-induced cardiac oxidative stress, inflammation, and heart failure development.Redox biology · 2026Article
- Article
- Interleukin-23 in lung and airway diseases: from pathogenesis to precision-guided therapeutic targeting.Frontiers in pharmacology · 2026Review
- Tyrosine kinase 2 inhibitors in the therapy of inflammatory and autoimmune diseases.Pharmacological reports : PR · 2025Review
- Cardiotrophin-like cytokine factor 1 forms a complex with IL12/IL23p40.Scientific reports · 2025Article
- Genetic inhibition of IL-12β suppresses systolic overload-induced cardiac inflammation and heart failure development.bioRxiv : the preprint server for biology · 2025Article
- Review
- Serum Cytokine Profile in IgA Nephropathy.Kidney medicine · 2025Article
- Xuetongsu attenuates synovial inflammation in rheumatoid arthritis by inhibiting the IL-23/IL-17/NF-κB inflammatory axis.Frontiers in pharmacology · 2025Article
- Pharmacological inhibition of IL12β is effective in treating pressure overload-induced cardiac inflammation and heart failure.Frontiers in immunology · 2025Article
- Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy.Clinical and experimental medicine · 2024Review
- Cut-off values for IL-21 and IL-23 as biochemical markers for pemphigus vulgaris.Journal of medicine and life · 2023Article
- Interleukin-23 Involved in Fibrotic Autoimmune Diseases: New Discoveries.Journal of clinical medicine · 2023Review
- Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023.Human vaccines & immunotherapeutics · 2023Review
- The presence, severity, and onset of preeclampsia is associated with maternal interleukin-23 level: A case-control study.International journal of reproductive biomedicine · 2023Article
- Single cell RNA-sequencing profiling to improve the translation between human IBD andFrontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeIL-23 is a central proinflammatory cytokine with a wide range of influence over immune response. It is implicated in several autoimmune diseases due to the infinite inflammatory loops it can create through the positive feedbacks of both IL-17 and IL-22 arms. This made IL-23 a key target of autoimmune disorders therapy, which indeed was proven to inhibit inflammation and ameliorate diseases. Current autoimmune treatments targeting IL-23 are either by preventing IL-23 ligation to its receptor (IL-23R) via antibodies or inhibiting IL-23 signaling by signaling downstream mediators' inhibitors, with each approach having its own pros and cons.
methodsLiterature review was done to further understand the biology of IL-23 and current therapies.
resultsIn this review, we discuss the biological features of IL-23 and its role in the pathogenesis of autoimmune diseases including psoriasis, rheumatoid arthritis and inflammatory bowel diseases. Advantages, limitations and side effects of each concept will be reviewed, suggesting several advanced IL-23-based bio-techniques to generate new and possible future therapies to overcome current treatments problems.
Indexed as
Identifiers
32215665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.